

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

Product

Name:	Biotechnology (the "Sub-Fund"), a sub-fund of DNB Fund (the "Fund")
ISIN:	LU2814038696
Class:	Institutional A (CHF) (the "Class")
Product manufacturer:	FundPartner Solutions (Europe) S.A. (the "Management Company"), part of Pictet Group.
Website:	https://assetservices.group.pictet/asset-services/fund-library/

Call +352 467171-1 for more information.

The Commission de Surveillance du Secteur Financier (CSSF) is responsible for supervising FundPartner Solutions (Europe) S.A. in relation to this Key Information Document. The Fund is authorised in Luxembourg. FundPartner Solutions (Europe) S.A. is authorised in Luxembourg and regulated by the Commission de Surveillance du Secteur Financier (CSSF).

This key information document is accurate as at 23rd September 2024.

What is this product?

TYPE OF PRODUCT

The product is a sub-fund of DNB Fund (the "Fund"), an Undertaking for Collective Investment in Transferable Securities (UCITS) under the laws of the Grand-Duchy of Luxembourg.

TERM

The Sub-Fund is established for an unlimited duration and liquidation must be decided upon by the board of directors.

OBJECTIVES

An aging population and growing healthcare costs is leading to a heightened need for continuous innovation within healthcare. Biotechnology presents a promising avenue for investing in concrete solutions which can potentially transform medical treatment and practice.

The biotechnology sector is experiencing a remarkable surge in growth and the ecosystem spans across geographies and market capitalizations. Ongoing scientific breakthroughs are opening unprecedented possibilities for disease treatment and prevention.

The industry has demonstrated its resilience and effectiveness in responding to the challenges posed by the pandemic, showcasing a track-record of continuous innovation, and establishing itself as a reliable investment stronghold.

In the long-run prices of financial assets are driven by their fundamental value. In the biotechnology sector the value creation is driven by the company's ability to innovate, develop and introduce new medicines, tools or devices to the market.

The identification of specific catalysts like for example clinical readouts, regulatory milestones and strategic deals which can drive value is important in the investment process. As such, technology platform, R&D capability and expertise is one of our key selection criteria.

Each equity sector has its own specific drivers and characteristics. Equities in the biotechnology sector trade with a wide range of possible outcomes, driven by the company's scientific success or failure.

We seek to find mispriced equities through research and reflection – our opportunities lie where our view deviates meaningfully from perceptions behind the current share price and where the risk of losing money is limited.

We believe in a fundamental bottom-up driven process, aiming for deep knowledge of the companies' current and future assets and possibilities to maximize opportunities and to manage risk.

To achieve its objective the sub fund will mainly invest in equities. Finally it promotes E/S characteristics, but will not make any sustainable investments.

The Sub-Fund may invest up to 20% of its net assets in emerging markets. The Sub-Fund will not invest in financial derivative instruments.

Benchmark: The Sub-Fund follows an actively managed strategy. The Sub-Fund's benchmark index is Nasdaq Biotech Index. The chosen benchmark is a standard benchmark reflecting the broad biotechnology investment universe relevant for the Sub-Fund.

ESG information: The Sub-Fund promotes, among other characteristics, environmental or social characteristics, and the companies in which the investments are made follow good governance practices in accordance with article 8 of SFDR. The Sub-Fund does not have a sustainable investment objective in accordance with article 9 of SFDR. Please refer to the Prospectus for more information.

Dividend policy: No dividends are intended to be distributed. Any income derived from the portfolio is reinvested.

INTENDED RETAIL INVESTOR

This share class is reserved for institutional investors. Investors must have experience with volatile products and should be aware that the value of the Sub-Fund may fall as well as rise and the invested capital may not be fully repaid. Investors must be able to accept significant temporary losses. The Sub-Fund is designed for the investment objective of building up capital with a Recommended Holding Period of 7 years.

OTHER INFORMATION

Depositary: Bank Pictet & Cie (Europe) AG, succursale de Luxembourg

Asset segregation: There is segregated liability between sub-funds of DNB Fund, meaning that the assets of a sub-fund will not be available to meet a claim of a creditor, or another third party made against another sub-fund.

Dealing: Investors may redeem shares on demand, on a daily basis. Please see the Prospectus for details.

Switching: Investors may switch between share classes or sub-funds of the Fund. Please see the Prospectus for details.

Additional information: More detailed information on the Fund, such as the prospectus, other classes, the key information, the latest Net Asset Value, the articles of incorporation as well as the latest annual and semi-annual report, can be obtained free of charge, in English, from the central administrator, the distributors, the Management Company or online at www.fundinfo.com and www.swissfunddata.ch.

This key information document describes the Class of one sub-fund of the Fund. For more information about other sub-funds, please refer to the prospectus and periodic reports that are prepared for the entire Fund.

What are the risks and what could I get in return?

Risk indicator



The risk indicator assumes you keep the product for 7 years.

The risk can be significantly different if you cash in at an early stage and you may get back less.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you. The essential risks of the investment fund lie in the possibility of depreciation of the securities in which the fund is invested.

Performance scenarios

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back. What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product and a suitable proxy over the last 12 years. Markets could develop very differently in the future.

Recommended holding period: Example investment		7 years CHF 10,000		
		If you exit after 1 year	If you exit after 7 years	
Scenarios				
Minimum	There is no minimum guaranteed return. You could lose some or all of your investment.			
Stress scenario	What you might get back after costs	CHF 4,980	CHF 2,890	
	Average return each year	-50.2%	-16.3%	
Unfavourable scenario	What you might get back after costs	CHF 6,900	CHF 8,890	This type of scenario occurred for an investment in the proxy then the product between August 2021 and August 2024.
	Average return each year	-31.0%	-1.7%	
Moderate scenario	What you might get back after costs	CHF 10,870	CHF 14,130	This type of scenario occurred for an investment in the proxy between June 2016 and June 2023.
	Average return each year	8.7%	5.1%	
Favourable scenario	What you might get back after costs	CHF 17,770	CHF 24,700	This type of scenario occurred for an investment in the proxy between December 2012 and December 2019.
	Average return each year	77.7%	13.8%	

The stress scenario shows what you might get back in extreme market circumstances.

What happens if FundPartner Solutions (Europe) S.A. is unable to pay out?

The Management Company is not making any payment to you in relation to this Sub-Fund and you would still be paid in case of a default from the Management Company.

The Sub-Fund's assets are held with a separate company, the Depositary, so the Sub-Fund's ability to pay out would not be affected by the insolvency of the Management Company. However, in the event of the Depositary's insolvency, or its delegates, the Sub-Fund may suffer a financial loss. However, this risk is mitigated to a certain extent by the fact the Depositary is required by law and regulation to segregate its own assets from the assets of the Sub-Fund. The Depositary will also be liable to the Sub-Fund or its investors for any loss arising from, among other things, its negligence, fraud or intentional failure properly to fulfill its obligations (subject to certain limitations).

If the Sub-Fund is terminated or wound up, the assets will be liquidated and you will receive an appropriate share of any proceeds but you may lose part or all of your investment.

There is no compensation or guarantee scheme protecting you from a default of the Depositary.

What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year you would get back the amount that you invested (0% annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.
- CHF 10,000 is invested.

Investment of CHF 10,000	If you exit after 1 year	If you exit after 7 years
Total costs	CHF 99	CHF 959
Annual cost impact (*)	1.0%	1.0%

(*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 6.1% before costs and 5.1% after costs.

Composition of costs

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	Up to We do not charge an entry fee for this Class. The person selling you this product may charge up to 5.00%.	Up to CHF 500
Exit costs	We do not charge an exit fee for this Class.	CHF 0
Ongoing costs taken each year		
Management fees and other administrative or operating costs	0.82% of the value of your investment per year. This percentage is based on an annualized estimation of the fees.	CHF 82
Transaction costs	0.17% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	CHF 17
Incidental costs taken under specific conditions		
Performance fees	10.00% of any increase of the Sub-Fund's net excess return above the benchmark: Nasdaq Biotech Index. Maximum amount of performance fee payable at year end may not exceed 5% of the Sub-Funds average value.	CHF 0

Conversions between sub-funds are subject to a commission of maximum 1% of the net asset value of the shares to be converted.

How long should I hold it and can I take my money out early?

Recommended holding period: 7 years.

The recommended holding period was chosen to provide a consistent return less dependent on market fluctuations.

A redemption order is executed at the redemption price ruling on a Business Day (a full business day on which banks are fully open in Luxembourg), the application for the redemption of shares must reach the Administration Agent (FundPartner Solutions (Europe) S.A.) before 1 p.m. (Luxembourg time) on the same Business Day.

How can I complain?

In the event a natural or legal person wishes to file a complaint with the Fund in order to recognize a right or to redress a harm, the complainant should address a written request that contains description of the issue and the details at the origin of the complaint, either by email (pfcs.lux@pictet.com), or by post, in an official language of their home country to the following address: FundPartner Solutions (Europe) S.A., 15 Avenue J.F. Kennedy, L-1855 Luxembourg. The Management Company's complaint handling procedure can be found on our website: <https://www.pictet.com/ch/en/legal-documents-and-notes/key-information-document-complaint-procedure>.

Other relevant information

More detailed information on the Fund, such as the prospectus, the articles of incorporation, the latest annual and semi-annual report as well as the latest NAVs per share, can be obtained free of charge, in English from the central administrator, the distributors, the representative in Switzerland, the Fund or online at www.swissfunddata.ch and www.fundinfo.com.

There is insufficient data to provide a useful indication of past performance to investors. The previous performance scenarios are available on the link: https://download.alphaomega.lu/perfscenario_LU2814038696_CH_en.pdf

Information for investors in Switzerland: The representative FundPartner Solutions (Suisse) S.A., 60, route des Acacias, 1211 Geneva, Switzerland. The paying agent is Banque Pictet & Cie S.A., 60, route des Acacias, 1211 Geneva, Switzerland.